Apr 4 |
Medical Devices Focused AngioDynamics Unveils Upbeat 2024 Financial Outlook, Stock Soars
|
Apr 4 |
AngioDynamics (ANGO) Q3 2024 Earnings Call Transcript
|
Apr 4 |
AngioDynamics Inc (ANGO) Posts Q3 Fiscal 2024 Results: A Mixed Performance Amidst Asset Divestiture
|
Apr 4 |
AngioDynamics gets FDA clearance for pulmonary embolism treatment device
|
Apr 4 |
AngioDynamics Non-GAAP EPS of -$0.16, revenue of $65.97M
|
Apr 4 |
AngioDynamics Reports Fiscal Year 2024 Third Quarter Financial Results; Updates Fiscal Year 2024 Guidance to Reflect Asset Divestiture
|
Apr 4 |
AngioDynamics Receives 510(k) Clearance for AlphaVac F1885 System in Treatment of PE
|
Apr 3 |
AngioDynamics Q3 2024 Earnings Preview
|
Apr 2 |
AngioDynamics (ANGO) Settles Patent Litigations With BD
|
Apr 1 |
AngioDynamics settles all patent litigation with C.R. Bard
|